FLEMINGTON, N.J., MAY 3 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD: NVDL) , a leading formulator of lingual spray drugs for systemic delivery through the oral mucosa, said its chief executive officer, Gary A. Shangold, MD, will present at the Rodman & Renshaw TechVest Global Healthcare Conference (May 12-14) at Claridge's Hotel, London, UK.
Dr. Shangold will be presenting in the French Salon on Wednesday, May 12 at 9:25am BST, British Summer Time (4:25am EDT).
A webcast of the presentation will be available on the date of the presentation and will be archived for 90 days. For details go to http://www.rodmanandrenshaw.com/.
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the- counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.
Contact: Barry C. Cohen Thomas Redington VP New Business 203-222-7399 & New Product 212-926-1733 Development email@example.com 908.782.3431 ext. 31 NovaDel Pharma Inc.
NovaDel Pharma, Inc.
CONTACT: Barry C. Cohen, VP New Business & New Product Development ofNovaDel Pharma Inc. +1-908-782-3431 ext. 31; or Thomas Redington,+1-203-222-7399, +1-212-926-1733, or firstname.lastname@example.org, for NovaDelPharma, Inc.